ReviewFrontiers in endocrinology2026
Molecular mechanisms and preclinical evidence of natural products in diabetic osteoporosis: a review.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic osteoporosis (DOP) is a prevalent and severe skeletal complication of diabetes, characterized by reduced bone mass, impaired bone microarchitecture, and elevated fracture risk. Its pathogenesis involves multiple interconnected mechanisms, including hyperglycemia-induced accumulation of advanced glycation end products (AGEs), oxidative stress, chronic inflammation, immune dysregulation, and programmed cell death of bone-related cells. Conventional therapies targeting single pathways often yield limited benefits, underscoring the need for alternative approaches. Traditional natural products and herbal formulations have long been used as complementary strategies for DOP prevention and treatment, exhibiting multifaceted protective effects. Experimental studies have demonstrated that bioactive compounds derived from these products can attenuate AGEs toxicity, reduce oxidative stress, modulate inflammation within the bone microenvironment, and regulate osteoblast and osteoclast apoptosis, autophagy, ferroptosis, and pyroptosis, thereby restoring the balance between bone formation and resorption. Some compounds also influence epigenetic regulation and cellular senescence and indirectly contribute to bone remodeling through modulation of gut microbiota, bone angiogenesis, and endocrine signaling. Stimulus-responsive delivery systems have been investigated to enhance bioavailability and bone-targeting efficiency. This review provides a comprehensive and updated overview of natural products and their active constituents in DOP management, highlighting underlying molecular mechanisms and potential therapeutic targets to support rational application and drug development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.